Skip to main content
Log in

Iometopane

123I β-CIT, Dopascan Injection, GPI 200, RTI 55

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Guilford Pharmaceuticals Inc. Guilford Pharmaceuticals Announces DRL Files Marketing Application for DOPAS-CAN(R) Injection Filed in Japan. Media Release: 10 Jul 2003. Available from URL: http://www.guilfordpharm.com

    Google Scholar 

  2. Guilford Pharmaceuticals and Parkinson Study Group announce positive clinical results with DOPASCAN (Rm), Parkinson’s disease diagnostic agent. PR Newswire [online]: 9 Jun 1997. Available from URL: http://www.newspage.com

    Google Scholar 

  3. Gatley SJ, Volkow ND, Chen R. Displacement of RTI-55 from the dopamine transporter by cocaine. European Journal of Pharmacology 296: 145–151, 25 Jan 1996

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iometopane. Drugs R&D 4, 320–322 (2003). https://doi.org/10.2165/00126839-200304050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304050-00008

Keywords

Navigation